| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nuvectis Pharma, Inc.$18.35
-0.93 (-4.9%)
C 45Pipeline Score Fair Value Pharma · Clinical
Market Cap
274.54 M
EPS
-1.28
P/E Ratio
-
Value Trade
645.83 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
4.11 M
Operating CF
-6.51 M
Total Assets
25.40 M
Total Liabilities
11.18 M
Equity
14.22 M
D/E Ratio
12,345
-15.37 %
Week
20.21 %
1 Month
22.49 %
3 Month
75.42 %
6 Month
162.03 %
5 Year
162.03 %
All Time
Cash Data
Cash Position
25.13 M
Monthly Burn
2.17 M
Runway
9.6 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
224.44 K
52 Week Range
5.55 - 13.34
% held by Insiders
42.78 %
% held by Institutions
14.45 %
Enterprise Value
249.41 M
Total Shares
26.53 M
Short %
8.7 %
Float Shares
17.99 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nuvectis Pharma, Inc.
204Total events
1Upcoming
19Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 1
Event history 203
Q3 2026
◆Topline ReadoutNXP900Clinical Data
Preliminary data readout from NXP900 Phase 1b study expected in summer 2026
oncologysource ↗
Jun 29, 2026
▼Equity OfferingCorporate
Pricing of $100 million public offering of common stock at $20.00 per share
Jun 22, 2026
▲Partnership / LicenseCorporate
Nuvectis in-licenses ex-China rights for NXP100 and NXP200 from Haisco
Jun 22, 2026
◆NMPA NDA ApprovalNXP100Ex-US Regulatory
MAA under NMPA review for NXP100 in C5 inhibitor-failed PNH patients
Paroxysmal Nocturnal Hemoglobinuria (PNH)source ↗
Jun 22, 2026
◆Trial InitiationNXP100Trial
Phase 3 trial ongoing in IgAN
Immunoglobulin A Nephropathy (IgAN)source ↗
Jun 22, 2026
May 19, 2026
◆Oral PresentationPresentation
Nuvectis management to present at H.C. Wainwright 4th Annual BioConnect Investor Conference
May 5, 2026
◆Enrollment UpdateNXP900Trial
NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US
oncologysource ↗
Apr 22, 2026
◆Poster PresentationNXP900Presentation
Resistance to SFK inhibitor NXP900 in cholangiocarcinoma characterized by IL13RA2-AKT signaling
cholangiocarcinomasource ↗
Apr 21, 2026
◆Poster PresentationNXP900Presentation
Targeting MDSCs to restore antitumor immunity in NSCLC via SRC family kinase inhibition with NXP900
NSCLCsource ↗
Drug Pipeline Intelligence
C45
Pipeline Score $393M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.4x
rNPV / MCap Top 66%
Micro Cap (rank 311 of 911)
Percentile RankNuvectis Pharma, Inc. carries a moderate pipeline score (45/100), with $5.0B risk-adjusted pipeline value, led by NXP800 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NXP800 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05226507 | 10% | $3.4B | ACTIVE NOT_RECRUITING | 45 | SLOW | C (44) | Dec 1, 2025 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NXP900 | — | Phase 1a | 2025-10-27 | favorable safety profile; significant pharmacodynamic responses; deep and sustained pharmacodynamic response in clinically relevant doses Read More | Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More | |
NXP900 | — | Phase 1a | 2025-10-27 | favorable safety profile; significant pharmacodynamic responses; deep and sustained pharmacodynamic response in clinically relevant doses Read More | Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More | |
NXP900 | — | Phase 1a | 2025-10-27 | favorable safety profile; significant pharmacodynamic responses; deep and sustained pharmacodynamic response in clinically relevant doses Read More | Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NVCT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NVCT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NVCT▼ -35.5%on this news
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Nuvectis Pharma has announced the pricing of its public offering, selling 5 million shares at $20 each, aiming to raise $100 million. The proceeds will support the development of its drug candidates NXP100, NXP200, and NXP900. The offering is set to close around July 1, 2026, pending customary conditions.
Read more →NVCT▲ +19.6%on this news· ran to +102% by day 3
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Nuvectis Pharma has entered a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds: NXP100, a complement Factor B inhibitor, and NXP200, a paradox-breaker BRAF inhibitor. This strategic expansion aims to enhance Nuvectis's pipeline in complement-mediated diseases and oncology. Both compounds are in late-stage development, with significant market potential.
Read more →NVCTNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Nuvectis Pharma, Inc. will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. CEO Ron Bentsur will present the company's innovative oncology treatments, including the clinical-stage drug candidate NXP900. The presentation will be available via webcast, highlighting Nuvectis' commitment to addressing unmet medical needs in cancer care.
Read more →NVCT▲ +9.2%on this news· ran to +31% by day 3
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma reported its Q1 2026 financial results, highlighting the ongoing enrollment in the NXP900 Phase 1b clinical program. The company presented preclinical data at the AACR Annual Meeting, demonstrating the efficacy of NXP900 in combination with sotorasib for treating non-small cell lung cancer. Despite a rise in net loss and reduced cash reserves, Nuvectis remains focused on achieving key clinical milestones.
Read more →NVCTNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma has announced that it will present its drug candidate NXP900 at the 2026 American Association for Cancer Research Meeting in San Diego. NXP900 is an oral small molecule inhibitor targeting SRC Family of Kinases, which has completed a Phase 1a study and initiated Phase 1b. This presentation highlights the company's commitment to developing innovative oncology treatments.
Read more →NVCTNuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. reported its 2025 financial results, highlighting progress in the NXP900 development program. The company anticipates multiple data readouts in 2026 from its ongoing Phase 1b studies. Despite a net loss increase, Nuvectis maintains a strong cash position, expected to support its operations through 2027.
Read more →NVCTNuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Nuvectis Pharma has announced the initiation of a Phase 1b study for NXP900 in combination with osimertinib for patients with EGFRmut+NSCLC. This study follows a successful Phase 1a dose escalation and aims to explore the safety and efficacy of the combination therapy. Eligible patients include those who have previously responded to osimertinib. The company anticipates multiple data readouts in 2026.
Read more →NVCTNuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Nuvectis Pharma will host a virtual Key Opinion Leader Meeting on December 2, 2025, to discuss the NXP900 Phase 1b program for advanced solid tumors, including its combination with osimertinib for non-small cell lung cancer. The event will feature expert discussions on preclinical and clinical data, followed by a Q&A session. NXP900 is a selective SRC/YRS1 kinase inhibitor currently undergoing clinical trials.
Read more →NVCT▼ -7.5%on this news
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. reported its third quarter 2025 financial results, highlighting a focus on advancing the Phase 1b program for NXP900. The company noted an increase in cash reserves to $35.4 million, but also reported a net loss of $7.5 million, attributed to milestone expenses and clinical study costs. Despite the losses, the emerging clinical profile of NXP900 is promising, with ongoing studies aimed at showcasing its therapeutic potential.
Read more →NVCT▼ -7.5%on this newsshared move
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. reported its Q3 2025 financial results, highlighting advancements in its Phase 1b program for NXP900. The company has seen a significant increase in cash reserves, now totaling $35.4 million. However, it also reported a net loss of $7.5 million, influenced by milestone expenses and increased operational costs.
Read more →NVCT▲ +5.6%on this news
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma presented highlights for NXP900 at the 2025 AACR-NCI-EORTC conference. The Phase 1a studies indicated a favorable safety profile and significant pharmacodynamic responses. The company is advancing to the Phase 1b program, focusing on biomarker patient selection. CEO Ron Bentsur expressed optimism about NXP900's potential as a leading SRC/YES1 inhibitor.
Read more →NVCTNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma, Inc. has announced upcoming poster presentations for its drug NXP900 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025. The presentations will focus on clinical safety, pharmacokinetics, and the drug's effectiveness in inhibiting tumor growth in specific cancer models. Continued development of NXP900 underscores the company's commitment to addressing serious unmet medical needs in oncology.
Read more →NVCTNuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Nuvectis Pharma has appointed Dr. Juan Sanchez to its Board of Directors. Dr. Sanchez, a seasoned biotech executive, brings over 30 years of experience, including significant roles in corporate communications and investor relations. His appointment comes as Nuvectis prepares to launch its Phase 1b program for NXP900, aimed at treating advanced cancers.
Read more →NVCTNuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Nuvectis Pharma, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Ron Bentsur will present a corporate overview available for on-demand viewing starting September 5, 2025. The conference will include virtual one-on-one meetings from September 8-10, 2025, highlighting the company's focus on oncology treatments.
Read more →NVCT▲ +11.3%on this news
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
Nuvectis Pharma has announced the initiation of its Phase 1b program for NXP900, following successful preliminary studies. The program will evaluate NXP900 both as a single agent and in combination with existing cancer therapies. The company is optimistic about the drug's potential to address significant unmet medical needs in oncology, supported by a strong dataset and investor confidence.
Read more →NVCT▼ -5.3%on this news· ran to -18% by day 3
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advance
Nuvectis Pharma, Inc. released its financial results for Q2 2025, highlighting significant progress, including the completion of Phase 1a studies for its lead drug candidate, NXP900. The company reported a cash position of approximately $39 million, expected to fund operations until the second half of 2027. However, they also noted a net loss increase compared to the same period last year, primarily due to rising operating expenses. Plans to explore NXP800 for additional cancer types signal ongoing development efforts amidst these financial challenges.
Read more →NVCT▼ -7.8%on this newsshared move
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Nuvectis Pharma has provided a final update on the Phase 1b study of NXP800 in ovarian cancer, reporting partial responses in some patients but deciding to halt its development in this indication. The company will instead focus on advancing NXP900, which has completed its Phase 1a dose escalation study and is set to enter Phase 1b soon. The findings suggest NXP800 may have potential in other cancer types.
Read more →NVCTNuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
Nuvectis Pharma has successfully completed a drug-drug interaction study for its candidate NXP900, which supports its potential as a combination partner with leading therapies. The company is advancing NXP900 into a Phase 1b program, aiming to explore its therapeutic potential in patients with advanced cancers. The CEO expressed optimism about NXP900's unique mechanism of action and its expected wide therapeutic window.
Read more →NVCT▲ +6.4%on this news· ran to +18% by day 1
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. is scheduled to present at the upcoming H.C. Wainwright Global BioConnect Investor Conference on May 20, 2025. CEO Ron Bentsur will deliver insights about their progress and developments in precision medicine targeting serious unmet medical needs in oncology. The company is advancing two clinical-stage drug candidates, NXP800, for specific cancers, and NXP900, which inhibits SRC Family Kinases. This presentation aims to enhance investor awareness and interest in Nuvectis' therapeutic innovations.
Read more →NVCTNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 AACR conference demonstrated robust pharmac
Nuvectis Pharma, Inc. reported its first quarter 2025 financial results, highlighting significant progress in its clinical programs. Notably, the company presented promising clinical data for NXP900 at the AACR conference, showing robust preliminary efficacy and safety. The financial report indicated a cash balance increase to $29.9 million, primarily due to a successful public offering. Despite a rise in net loss compared to the previous year, Nuvectis is optimistic about upcoming milestones for its drug candidates.
Read more →NVCTNuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
Nuvectis Pharma has provided highlights from the 2025 AACR Meeting regarding NXP900, a drug currently undergoing clinical trials. The Phase 1a study indicated that NXP900 is well-tolerated and exhibits significant pharmacodynamic responses at increased doses. The preclinical data strengthens the rationale for developing NXP900 as both a single-agent treatment and in combination with other market-leading therapies for non-small cell lung cancer (NSCLC). The Phase 1b program is expected to start soon, targeting advanced cancers with specific biomarker alterations.
Read more →NVCTNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. has announced several upcoming presentations for its drug candidate NXP900 at the 2025 American Association for Cancer Research Meeting in Chicago. Scheduled for April 29, these presentations will cover a series of studies, including results from its Phase 1 trial targeting advanced solid tumors and overcoming resistance in non-small cell lung cancer (NSCLC). NXP900, a first-in-class SRC family kinase inhibitor, is currently in clinical development and aims to address significant unmet medical needs in oncology. The drug's unique mechanism of action allows it to effectively inhibit crucial signaling pathways associated with tumor progression.
Read more →NVCT▲ +6%on this news
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Nuvectis Pharma, Inc. has announced its participation in the 37th Annual Roth Conference, where CEO Ron Bentsur will host a fireside chat. The event is scheduled for March 17-19, 2025, in Dana Point, California. The company is actively developing two drug candidates, NXP800 and NXP900, which are undergoing clinical trials for severe oncology conditions. This participation highlights Nuvectis's commitment to addressing unmet medical needs in cancer treatment.
Read more →NVCTNuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
Nuvectis Pharma announced a new publication indicating that the combination of NXP900 and the EGFR inhibitor osimertinib enhances treatment effectiveness in preclinical models of EGFR mutated non-small cell lung cancer (NSCLC). The research shows improved outcomes, such as reduced cell proliferation and increased apoptosis, supporting further investigation of NXP900 in clinical settings. The findings align with prior research on reversing resistance to osimertinib, leading to optimism about NXP900's potential in addressing unmet medical needs in oncology.
Read more →NVCT▼ -5.8%on this news
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S
Nuvectis Pharma, Inc. announced its financial results for 2024, highlighting progress in its drug development pipeline. The company received Orphan Drug Designation for NXP800, which is currently in a Phase 1b trial for ARID1a-mutated ovarian cancer. NXP900 is also advancing in clinical trials, with enrollment ongoing. Nuvectis successfully raised $15.5 million, enhancing its financial stability as it looks to generate significant results in the coming year.
Read more →NVCT▼ -7.3%on this news
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
Nuvectis Pharma, Inc. announced the successful closing of a public offering of 2,700,000 shares of common stock at $5.00 per share, totaling approximately $15.5 million. Additionally, the underwriter exercised its option to purchase 405,000 more shares, demonstrating strong investor interest. The funds will be used to advance the development programs of their drug candidates NXP800 and NXP900, as well as for general corporate purposes. The company focuses on innovative precision medicines for oncology and is currently conducting clinical trials for its candidates.
Read more →NVCTNuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
Nuvectis Pharma, Inc. announced the pricing of its public offering of 2,700,000 shares of common stock at $5.00 per share, expected to generate gross proceeds of $13.5 million. The company plans to use the net proceeds to advance its drug development programs, particularly for NXP800 and NXP900. The closing of the offering is anticipated on February 6, 2025. Lucid Capital Markets is the sole book runner for the offering, which follows Nuvectis's shelf registration statement declared effective by the SEC in March 2023.
Read more →NVCTNuvectis Pharma Announces Proposed Public Offering of Common Stock
Nuvectis Pharma has announced a proposed underwritten public offering of its common stock to raise funds for its drug development programs. The company plans to grant underwriters a 30-day option to purchase additional shares. Proceeds will be used to support clinical trials of its drug candidates NXP800 and NXP900, alongside other corporate needs. The offering is contingent upon market conditions, with no guarantee on its timing or success.
Read more →NVCTNuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Nuvectis Pharma, Inc. announced that Ron Bentsur, its CEO, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium on December 12, 2024. The company focuses on developing precision medicines for serious oncology conditions and is advancing clinical-stage candidates NXP800 and NXP900. NXP800 targets platinum-resistant ARID1a-mutated ovarian carcinoma, while NXP900 inhibits SRC Family Kinases, currently in clinical trials.
Read more →NVCT▼ -46.3%on this news
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma has reported encouraging interim data from its Phase 1b study of NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer. The trial demonstrated antitumor activity with promising responses, particularly after modifying the dosing schedule to reduce side effects such as thrombocytopenia. The study has also received important FDA designations, highlighting NXP800's potential in a largely unmet medical need. Ongoing enrollment seeks to further evaluate higher dose intensities in upcoming patient cohorts.
Read more →NVCT▲ +17.7%on this news· ran to +71% by day 3
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment
Nuvectis Pharma, Inc. released its third quarter 2024 financial results, indicating progress in its drug development initiatives. The company is expecting an update on clinical data from its NXP800 Phase 1b study later this month, which has now also received Orphan Drug Designation. The NXP900 program has cleared dose escalation cohorts without any major toxicities reported. Nuvectis' current cash position is projected to support its development milestones through 2026.
Read more →NVCT▲ +5.3%on this news
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma has announced its upcoming presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium in Barcelona, Spain. The presentations will showcase NXP900, a novel YES1/SRC kinase inhibitor currently in Phase 1 clinical trials. One of the studies demonstrates its potent synergy with ALK inhibitors, while another focuses on identifying biomarkers for treatment response. These developments reflect Nuvectis's commitment to addressing unmet needs in oncology.
Read more →NVCTNuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Nuvectis Pharma, Inc. announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York. The panel discussion will focus on innovative therapies for solid tumors, reflecting the company's commitment to advancing treatments in oncology. Nuvectis is developing two clinical-stage drug candidates, NXP800 and NXP900, both of which address serious unmet medical needs. NXP800 has received multiple FDA designations, indicating its potential in the market.
Read more →NVCT▼ -6.8%on this news
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Nuvectis Pharma, Inc. announced that its CEO, Ron Bentsur, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. The company is engaged in the development of precision medicines aimed at serious oncology conditions. Nuvectis is advancing two clinical-stage drug candidates, NXP800 and NXP900, with NXP800 already receiving Fast Track Designation from the FDA for certain ovarian cancer indications. This presentation highlights the company's commitment to addressing unmet medical needs in oncology.
Read more →NVCTNuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Nuvectis Pharma has announced that its drug candidate NXP800 has been granted Orphan Drug Designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. This designation is significant as it validates the drug's mechanism of action and its relevance to a specific patient population. The company anticipates providing updates from its ongoing Phase 1b clinical trial in the near future. Orphan Drug Designation can lead to financial incentives and a potential seven years of market exclusivity if the drug receives approval.
Read more →NVCT▼ -5.8%on this news
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma, Inc. has reported its financial results for the second quarter of 2024, showing a net loss of $4.4 million, which is an improvement compared to the previous year's loss. The company continues to advance its clinical programs for NXP800 and NXP900, with ongoing trials in various cancer types. The company's cash balance decreased slightly, prompting attention to its financial sustainability as trials continue and additional updates are expected by the end of 2024.
Read more →NVCTNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 20, 2024, in New York City. Ron Bentsur, the company's Chairman and CEO, will lead the presentation. Nuvectis focuses on precision medicines for serious oncology conditions and is advancing clinical-stage drug candidates NXP800 and NXP900. NXP800 has received both Fast Track and Orphan Drug Designations from the FDA, underscoring its clinical significance.
Read more →NVCTNuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a pro
Nuvectis Pharma, Inc. reported its first quarter 2024 financial results, highlighting progress in its clinical development programs for NXP800 and NXP900. The company revealed promising preliminary data from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, alongside improved patient enrollment. Additionally, new preclinical data for NXP900 were presented, indicating potential advantages in treating non-small cell lung cancer. The company reported a cash balance of approximately $19.5 million, providing operational runway into the second half of 2025.
Read more →NVCTNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma presented findings from the AACR conference, showcasing NXP900's efficacy in overcoming resistance in non-small cell lung cancer (NSCLC) cells. The data highlighted that combining NXP900 with osimertinib significantly reverses drug resistance. Additionally, NXP900 showed strong single-agent activity in ALK-resistant NSCLC cells. As the Phase 1a dose escalation study proceeds, Nuvectis expresses optimism about NXP900's potential in addressing critical treatment gaps.
Read more →NVCT▼ -16.1%on this news
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. has announced its upcoming presentations of drug candidates NXP800 and NXP900 at the 2024 American Association for Cancer Research Meeting. The presentations will cover various aspects of NXP800, including its pharmacokinetics, mechanisms of action, and its potential as a treatment for platinum-resistant ovarian cancer and cholangiocarcinoma. NXP900 will also be featured, showcasing its efficacy against human cholangiocarcinoma in preclinical models. The conference is set to take place from April 5 to 10 in San Diego, California.
Read more →NVCT▲ +20.2%on this newsshared move
Nuvectis Pharma to Present at the 36th Annual Roth Conference
Nuvectis Pharma, a biopharmaceutical company focused on precision medicines for oncology, will present at the 36th Annual Roth Conference on March 19, 2024. CEO Ron Bentsur will be leading the presentation, highlighting Nuvectis's ongoing developments, including two drug candidates, NXP800 and NXP900. NXP800 has obtained Fast Track Designation from the FDA and is currently in clinical trials for various cancer types. NXP900 is also undergoing a Phase 1a dose escalation study.
Read more →NVCT▼ -5.1%on this newsshared move
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma announced promising preliminary results from their Phase 1b clinical trial of NXP800 for treating platinum-resistant ARID1a-mutated ovarian cancer. The trial demonstrated a 33% response rate and a 100% disease control rate in evaluated patients. Among the four patients, one had a complete response in non-target tumor, while the others showed stable disease. Despite some adverse events like thrombocytopenia and gastrointestinal issues, the data signals the potential effectiveness of NXP800 in treating this difficult cancer type, supported by FDA's Fast Track Designation.
Read more →NVCTNuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a
Nuvectis Pharma, Inc. shared its fiscal year 2023 financial results, reporting a net loss of $22.3 million, up from $19.1 million the previous year. The company highlighted the progress of its two drug candidates, NXP800 and NXP900, with NXP800's Phase 1b study in platinum-resistant ARID1a-mutated ovarian cancer set to provide preliminary data soon. Despite a decrease in cash reserves to $19.1 million, Nuvectis remains focused on developing innovative treatments for unmet medical needs in oncology.
Read more →NVCTNuvectis Pharma Announces Participation at Upcoming Investor Conferences
Nuvectis Pharma, Inc. has announced its participation in upcoming investor conferences, showcasing its ongoing efforts to connect with investors. The Chairman and CEO, Ron Bentsur, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024, and at the 2024 NeauxCancer Oncology Conference on March 1, 2024. The company is focused on developing precision medicines for serious oncology conditions, with two drug candidates, NXP800 and NXP900, currently under development. NXP800 has received Fast Track and Orphan Drug Designations from the FDA for specific oncology indications.
Read more →NVCTNuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nuvectis Pharma, a clinical-stage biopharmaceutical company focused on innovative oncology treatments, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Ron Bentsur will discuss the company's promising drug candidates, including NXP800 and NXP900. NXP800 is currently undergoing a Phase 1b clinical trial for platinum-resistant, ARID1a-mutated ovarian carcinoma and has received FDA Fast Track and Orphan Drug designations. NXP900 is in Phase 1a development as a SRC/YES1 kinase inhibitor.
Read more →NVCTNuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
Nuvectis Pharma, Inc. has announced a collaboration with the Mayo Clinic to evaluate its drug candidate NXP800 in a clinical trial for cholangiocarcinoma. Dr. Mitesh Borad from Mayo Clinic will be the principal investigator for this study, which follows encouraging preclinical data. NXP800 has already received orphan drug designation from the FDA for its use in treating cholangiocarcinoma, highlighting the drug's potential for addressing unmet medical needs in oncology.
Read more →NVCT▼ -7.8%on this news
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a
Nuvectis Pharma, Inc. announced its third quarter 2023 financial results, revealing a net loss of $5.9 million. The company is focusing on the development of its lead candidates, NXP800 and NXP900, with ongoing Phase 1b studies for NXP800 in treating platinum-resistant, ARID1a-mutated ovarian carcinoma. The FDA has granted Orphan Drug Designation for NXP800 in cholangiocarcinoma, while the company maintains $22.1 million in cash to support its clinical programs through 2025. Nuvectis aims to meet key milestones in its investigations of these drug candidates.
Read more →NVCTNuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
Nuvectis Pharma, Inc. announced an upcoming scientific presentation for its drug candidate NXP800 at the 2023 AACR Special Conference on Endometrial Cancer. The presentation will detail NXP800's activity in specific endometrial cancer xenograft models, emphasizing its potential as a targeted therapy. NXP800 is currently in a Phase 1b clinical trial for treating platinum-resistant ARID1a-mutated ovarian carcinoma and has received important FDA designations. This event signifies a critical opportunity for Nuvectis to showcase its research at a leading oncology conference.
Read more →NVCTNuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Nuvectis Pharma, Inc. has announced an updated date and time for its corporate presentation at the 2023 Cantor Global Healthcare Conference. CEO Ron Bentsur will present on September 26, 2023, at 12:25 PM ET in New York. The company is focused on precision medicines for oncology and is progressing on drug candidates NXP800 and NXP900, both of which have received regulatory designations from the FDA.
Read more →NVCTNuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Nuvectis Pharma, Inc. has announced upcoming scientific presentations for its investigational drugs NXP800 and NXP900 at two significant oncology conferences. NXP800 will be featured in discussions focused on ARID1A-mutated ovarian cancer, while both NXP800 and NXP900 will be presented at the International Conference on Molecular Targets and Cancer Therapeutics. The presentations underscore the company's commitment to addressing unmet medical needs in oncology through innovative precision medicines.
Read more →NVCTNuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
Nuvectis Pharma, Inc. has announced the initiation of a Phase 1a dose escalation clinical trial for NXP900, an innovative inhibitor targeting the SRC/YES1 kinase family. This trial aims to assess the safety, tolerability, and pharmacokinetic properties of NXP900 in patients with advanced solid tumors. The drug has shown promising anti-cancer activity in preclinical models, which supports its potential as a treatment option. Nuvectis believes NXP900's unique mechanism sets it apart from other multi-kinase inhibitors in development.
Read more →NVCTNuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Nuvectis Pharma, Inc. announced it will host a virtual KOL event on September 14, 2023, to discuss its two clinical-stage drug candidates, NXP800 and NXP900. The event will feature key opinion leaders, including Dr. Bradley Monk and Dr. Ramez Eskander, who will present clinical development opportunities, particularly for NXP800 in treating platinum-resistant ovarian cancer. The discussions will be followed by a live question-and-answer session, emphasizing the company's commitment to advancing precision medicine in oncology.
Read more →NVCTNuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
Nuvectis Pharma has announced that its drug NXP800 has received Orphan Drug Designation from the FDA for the treatment of cholangiocarcinoma. This designation highlights the urgent need for innovative therapies for this aggressive cancer, which currently has limited treatment options. NXP800, an oral small molecule, has shown promising results in preclinical studies and is currently being evaluated in a Phase 1b clinical trial for ARID1a-mutated ovarian carcinoma. The Orphan Drug Designation also grants potential financial incentives and marketing exclusivity upon approval.
Read more →NVCTNuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights The Phase 1b study of NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma is ongoing NXP900 IND cleared
Nuvectis Pharma, Inc. reported its second quarter 2023 financial results, indicating significant advancement in its drug development programs. The ongoing Phase 1b trial of NXP800 for platinum-resistant, ARID1a-mutated ovarian carcinoma is expected to yield preliminary data in early 2024. Additionally, the FDA has cleared the IND for NXP900, with a Phase 1a trial scheduled to begin this quarter. Despite these developments, the company recorded a net loss of $5.7 million for the quarter, an increase in expenses attributed to R&D and compensation costs.
Read more →NVCTNuvectis Pharma Set to Join the Russell 2000 and Russell 3000 Indexes
Nuvectis Pharma, Inc. has announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 23, 2023. The company focuses on developing precision medicines for oncology, currently advancing drug candidates NXP800 and NXP900. NXP800 is in a Phase 1b study and has received FDA Fast Track Designation for addressing a particular type of ovarian cancer. NXP900 is on track for Phase 1a study initiation after FDA IND clearance, showcasing the company's commitment to innovative cancer therapies.
Read more →NVCT▲ +6.2%on this news
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
Nuvectis Pharma, Inc. has announced the FDA clearance of its Investigational New Drug Application for NXP900, marking a significant milestone in its clinical development program. The Phase 1 clinical trial protocol for NXP900 is intended to explore its efficacy against serious cancer conditions where unmet medical needs exist. With its unique mechanism of action, NXP900 demonstrates potential antitumor activity and the ability to tackle acquired drug resistance in certain cancers. The initiation of the Phase 1a study is anticipated in the coming months.
Read more →NVCTNuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer Initiated IND and Phase 1a Study for NXP900 Pending
Nuvectis Pharma, Inc. reported its first quarter 2023 financial results, highlighting key advancements in its drug development pipeline. The company initiated a Phase 1b study for its drug candidate NXP800, aimed at treating platinum-resistant ARID1a-mutated ovarian cancer, and is preparing to commence a Phase 1a trial for NXP900, which has a pending IND application. Financially, Nuvectis faces challenges with increased net losses and decreased cash reserves. However, recent research supports the potential for NXP800 to also target cholangiocarcinoma, expanding its development opportunities.
Read more →NVCTNuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
Nuvectis Pharma provided highlights on NXP800 during a poster presentation at the 2023 AACR Annual Meeting. The drug showcased significant antitumor activity in cholangiocarcinoma patient-derived xenograft models, raising optimism about its potential clinical benefits. The company's CEO emphasized the unmet medical need in cholangiocarcinoma treatment, while the research team leader noted the promising preclinical results. Nuvectis Pharma is actively exploring further clinical development opportunities for NXP800.
Read more →NVCTNuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Nuvectis Pharma has announced the initiation of a Phase 1b clinical study for its drug NXP800 in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. This multicenter study aims to assess the safety, tolerability, and preliminary efficacy of NXP800, an oral small molecule inhibitor of the HSF1 pathway. The trial will enroll approximately 50 patients across the U.S., UK, and Europe and will explore two dosing regimens. This development follows encouraging results from earlier studies and has been facilitated by the FDA's Fast Track Designation for NXP800.
Read more →NVCT▲ +5.7%on this news
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. announced that it will present its drug candidates, NXP800 and NXP900, at the upcoming 2023 American Association for Cancer Research Meeting. NXP800 is currently in a Phase 1a clinical study and has received Fast Track Designation from the FDA for a specific type of ovarian carcinoma. The company aims to demonstrate the therapeutic efficacy of both drug candidates through various presentations scheduled between April 14th and April 19th in Orlando, Florida. This visibility at a prominent conference may open opportunities for further research and partnerships.
Read more →NVCT▲ +7.7%on this news
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
Nuvectis Pharma, Inc. announced that its CEO, Ron Bentsur, will participate in a fireside chat at the 35th Annual Roth Conference on March 14, 2023. The company is dedicated to developing precision medicines for oncology, with two drug candidates in progress: NXP800, a clinical-stage oral small molecule for an advanced solid tumor, and NXP900, a novel SRC/YES1 kinase inhibitor with an IND submission pending. This event could boost Nuvectis's visibility and support its mission in addressing unmet medical needs in oncology.
Read more →NVCTNuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights NXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma ENGOT and GOG Found
Nuvectis Pharma, Inc. has reported its financial results for the fiscal year 2022, highlighting significant advancements in its drug development programs, particularly NXP800, which has received Fast Track Designation from the FDA for treating ARID1A-mutated ovarian carcinoma. The company is set to begin a Phase 1b clinical trial in this indication, further supported by the engagement of prominent clinical trial consortia. However, the financial report also noted a rise in net loss and administrative expenses, reflecting the costs associated with its recent public listing. The overall outlook remains positive as Nuvectis continues its focus on innovative oncology treatments.
Read more →NVCTNuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Nuvectis Pharma announced positive results from a recent poster presentation at the ESMO Gynecological Cancers Congress, highlighting the efficacy of NXP800 in inhibiting tumor growth in ARID1a-mutated ovarian carcinoma models. The findings demonstrate robust tumor growth inhibition rates of 70% and 82% compared with lower rates for cisplatin treatments. The results emphasize a significant need for new therapeutic options in this subset of ovarian cancer, prompting excitement for the upcoming Phase 1b clinical trial of NXP800.
Read more →NVCT▲ +7.3%on this news· ran to +30% by day 1
Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi
Nuvectis Pharma announced a publication in the Journal of Experimental Medicine regarding NXP900, a novel SRC/YES1 kinase inhibitor, in an in-vivo model of metastatic castration resistant prostate cancer resistant to enzalutamide. The study suggests that NXP900 could potentially reverse resistance to XTANDI and demonstrates its mechanism of action. The company is optimistic about NXP900 becoming a leading treatment option for several solid tumors, based on the data presented. This publication adds to the growing evidence supporting the clinical potential of NXP900.
Read more →NVCTNuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Nuvectis Pharma has announced a collaboration with the ENGOT and GOG Foundation to conduct the Phase 1b clinical trial of NXP800, targeting ARID1A-mutated ovarian carcinomas. This trial will take place in Europe and the United States under the leadership of prominent oncologists from leading institutions. The ongoing Phase 1a study has shown promising results, and this collaboration is expected to enhance trial design and access to renowned clinical centers. The company believes that the advancements leading to this trial could signify significant progress in treatment options for patients with these specific ovarian cancers.
Read more →NVCTNuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expect
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights November 8, 2022, Fort Lee, NJ - Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of innovative precision medici
Read more →NVCTNuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology
Read more →NVCTNuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced tha
Read more →NVCTNuvectis Pharma Announces Formation of a Scientific Advisory Board
FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the form
Read more →NVCTNuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced po
Read more →NVCTNuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced th
Read more →NVCTNuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023 NXP80
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights August 5, 2022, Fort Lee, NJ - Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of novel therapies for the trea
Read more →NVCTNuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,
Read more →NVCTNuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement July 27, 2022, Fort Lee, NJ - Nuvectis Pharma, Inc (Nasdaq: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of precision medicines for serious conditions
Read more →NVCT▲ +11.4%on this news
Nuvectis Pharma Announces FDA Clearance of IND for NXP800
FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that
Read more →NVCTNuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced pos
Read more →NVCT▼ -13.5%on this news
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that R
Read more →NVCT▼ -5.6%on this news· ran to +25% by day 3
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights Dose Escalation Portion of NXP800 Phase 1 NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR "New Drugs on the Horizon" Session NXP900 Preclinical Potency Agai
Read more →NVCTNuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights f
Read more →NVCTNuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights f
Read more →NVCT▲ +14.4%on this news· ran to +25% by day 3
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated of Phase 1a Clinical Trial fo
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated of Phase 1a Clinical Trial for Announced Promising Data for NXP900 in Triple Negati
Read more →NVCTNuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abs
Read more →NVCTNuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that
Read more →NVCT▲ +8.5%on this news
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
Data Published in Cancer Research, a journal of the American Association for Cancer Research Publication highlights potent activity of NXP900, a differentiated inhibitor of the SRC/YES1 Kinases Fort Lee, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT
Read more →NVCT▼ -20.5%on this news
Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock
New York, NY, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis”), a biopharmaceutical company that focuses on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology, today announced the closi
Read more →NVCTNuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
Fort Lee, NJ, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology, today announced t
Read more →NVCTNuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800
Fort Lee, NJ , Dec. 31, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology, today announced the
Read more →NVCTNuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
FORT LEE, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, announced today that it has licensed exclus
Read more →NVCTNuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund
Fort Lee, New Jersey, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (the “Company” or “Nuvectis”), a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology, today announced the comp
Read more →Competitive Position
How NVCT ranks across every disease it competes inCompetitive Position is a premium feature
See how NVCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial